Market Overview - The tightening liquidity is suppressing risk appetite, leading to a pullback in the market [5][8] - The Shanghai Composite Index closed at 3891.86, down 0.80%, while the Shenzhen Component Index fell 1.81% to 13478.06 [1][8] - The overall market saw a decline with 1008 stocks rising and 4372 stocks falling, with a total trading volume of 20059.05 billion [9] Economic Insights - Eurozone's March CPI preliminary year-on-year increase is 2.5%, with a month-on-month increase of 1.2% [15][16] - The People's Bank of China conducted a 325 billion yuan reverse repurchase operation with a rate of 1.40% [17][18] - China's Purchasing Managers' Index returned to the expansion zone in March, indicating economic recovery [19][20] Company Dynamics - **Lens Technology (300433.SZ)**: Reported a 2025 annual revenue of 744.10 billion yuan, up 6.46%, and a net profit of 40.18 billion yuan, up 10.87% [27][28] - **Kailai Ying (002821.SZ)**: Expected revenue growth of 19%-22% in 2026, with a 2025 revenue of 66.70 billion yuan, up 14.91% [29][30] - **China Duty Free Group (601888.SH)**: Reported a 2025 revenue of 536.94 billion yuan, down 4.92%, and a net profit of 35.86 billion yuan, down 15.96% [31][32] - **Reap Bio (300119.SZ)**: Achieved a net profit of 4.01 billion yuan in 2025, up 33% [33][34] - **Anhui Heli (600761.SH)**: Reported a revenue of 198.19 billion yuan, up 11.35%, with a net profit of 12.25 billion yuan, down 8.50% [35][36] - **Sany Heavy Industry (600031.SH)**: Achieved a net profit of 84.1 billion yuan in 2025, up 41.2%, with total revenue of 897 billion yuan [38][39] - **Zoomlion (000157.SZ)**: Reported a revenue of 521.07 billion yuan, up 14.58%, and a net profit of 48.58 billion yuan, up 38.01% [40] Industry Trends - The steel industry is undergoing deep adjustments, with companies focusing on high-end, intelligent, and green transformations [41] - The Chinese duty-free and tourism retail market is highly concentrated, with China Duty Free Group maintaining a leading position through its comprehensive layout and supply chain advantages [32]

Domestic Market Overview - The domestic market experienced a low opening followed by a rise, with the Shanghai Composite Index closing at 3913.72 points, up 0.63% [4][8] - The Shenzhen Component Index closed at 13760.37 points, up 1.13%, while the ChiNext Index rose by 0.71% [4][8] - A total of 25 out of 30 sectors in the CITIC industry classification saw gains, with significant increases in pharmaceuticals, basic chemicals, and non-ferrous metals [4][8] - The total trading volume of the A-share market was 186.38 billion yuan, continuing to decline from the previous day [4][8] Overseas Market Overview - The three major U.S. stock indices all closed lower, with the Dow Jones down 1.73%, the S&P 500 down 1.67%, and the Nasdaq down 2.15% [2][4] - Amazon's stock fell nearly 4%, leading the decline in the Dow [2][4] - The Nasdaq China Golden Dragon Index dropped by 1.90%, with notable declines in stocks like Pony.ai, which fell nearly 6% [2][4] Industry Insights - In the first two months of the year, the total profit of industrial enterprises above designated size reached 102.456 billion yuan, a year-on-year increase of 15.2%, accelerating by 14.6 percentage points compared to the previous year [9] - The revenue of these enterprises grew by 5.3% year-on-year, improving by 4.2 percentage points from the previous year, indicating favorable conditions for profit recovery [9] - Among 41 industrial categories, 26 saw profit growth accelerate or a reduction in decline, with over 60% of industries experiencing a rebound [9] News Highlights - Several small and medium-sized banks have lowered deposit rates, focusing on optimizing their deposit structures [10] - The Ministry of Ecology and Environment held a meeting to address air pollution prevention in the Yangtze River middle reaches urban agglomeration [11] - Two major aluminum plants in the Middle East were attacked, potentially impacting the global supply chain [13]

Core Viewpoint - Tianshan Aluminum is expected to achieve a net profit of 2.2 billion yuan in Q1 2026, representing a year-on-year increase of 107.92% [1] Group 1: General Performance Trends - The performance increase of Tianshan Aluminum reflects a broader trend among A-share companies, with many forecasting significant profit growth for Q1 2026 [2][3] - As of the report, 17 A-share companies have disclosed their Q1 2026 performance forecasts, with several, including Okoyi and Fuxiang Pharmaceutical, expecting net profit growth exceeding 100% [4] Group 2: Specific Company Forecasts - Okoyi anticipates a net profit of 180 million to 220 million yuan for Q1 2026, with a year-on-year growth rate of 2248.9% to 2770.9% [4] - Fuxiang Pharmaceutical expects a net profit of 52 million to 75 million yuan, marking a growth of 2222.67% to 3250.01% compared to the previous year [4] - Wanbang expects a net profit of 165 million yuan, reflecting a growth of 985.40% year-on-year [5] - Fuliwang forecasts a net profit of 40 million to 50 million yuan, with a growth rate of 183.84% to 254.81% [5] Group 3: Reasons for Performance Increases - The reasons for the expected profit increases vary by company, including improved industry conditions, new growth points, and low comparison bases from the previous year [6] - Okoyi cites rising raw material costs and increased production capacity as key factors for its growth [7] - Fuxiang Pharmaceutical benefits from the growing demand in the new energy sector, particularly in lithium battery materials [7] - Wanbang's transition from generic to innovative drugs has started to yield positive results, contributing to its performance [7] - Fuliwang attributes its growth to increased revenue from its 3C consumer electronics business and improved operational efficiency [8] - Tianshan Aluminum reports a 10% increase in aluminum production and a 17% rise in sales prices, alongside effective cost control [8]

Jiangsu Hengrui Pharmaceuticals Co., Ltd. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年3月25日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江苏恒瑞医药股份有限公司 2025 年年度报告摘要 公司代码：60027 ...

Key Points - The article discusses various important news and developments in the investment and business sectors, including stock offerings, government initiatives, and market trends. Group 1: Stock Offerings and Corporate Actions - Morning Light Electric will open for subscription on March 25, with an issue price of 15.50 yuan and a price-to-earnings ratio of 14.96 times, allowing a single account to subscribe up to 930,000 shares [2] - Ningbo Energy's stock price has shown unusual fluctuations, but its main business remains unchanged [11] - Xiamen Tungsten plans to acquire 69% of Jiujiang Dadi Mining for 295 million yuan [11] - Biwen Storage signed a procurement contract worth 1.5 billion USD with a storage manufacturer [14] - Companies like New Link Electronics and Sanquan Foods announced significant profit growth and share repurchase plans [14] Group 2: Government Initiatives and Economic Policies - The State-owned Assets Supervision and Administration Commission emphasized accelerating the layout of high-tech industries and guiding central enterprises to establish research institutions and high-tech companies in Xiong'an New Area [3] - The People's Bank of China will conduct a 500 billion yuan MLF operation on March 25 to maintain liquidity in the banking system [4] - Shanghai signed a strategic cooperation framework agreement with the National Social Security Fund Council to enhance collaboration in equity investment funds and major strategic projects [6] - The market regulatory authority held a meeting to focus on price supervision and anti-unfair competition, aiming to enhance the domestic market and promote high-quality development [8] Group 3: Market Trends and Industry Developments - Recent surges in oil prices have led to significant cost pressures on downstream paint companies, with over 20 major companies announcing price increases across various categories [9] - The first industry standard for embodied intelligent engineering robots was initiated in Chengdu, aiming to establish unified standards for product evaluation and safety [7]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The healthcare insurance fund is operating smoothly, with a total income of CNY 3.59 trillion and total expenditure of CNY 3 trillion in 2025, reflecting a stable operation of the fund [6][12]. - The report highlights the importance of focusing on sectors with individual stock alpha or defensive attributes amid increased market volatility due to external shocks [6][12]. - The report emphasizes the potential for price increases in the pharmaceutical sector, particularly in innovative drugs and high-end medical devices, supported by healthcare insurance policies [12]. - NVIDIA's GTC 2026 outlines a comprehensive strategy for integrating AI into the healthcare industry, indicating a significant transformation in the medical value chain [12][19]. Summary by Sections Industry Overview - The pharmaceutical and biotechnology sector has a total market capitalization of CNY 67,613.55 billion and a circulating market value of CNY 61,920.43 billion, with 504 listed companies [2]. Market Dynamics - The report notes that the Shanghai Composite Index fell by 2.19% and the pharmaceutical sector declined by 2.77%, ranking 8th among 31 sub-industries [6][19]. - The report identifies that the performance of individual stocks varies, with companies like Dong-E E-Jiao and China Resources Sanjiu showing positive profit growth [12]. Company Performance - Key recommended stocks include WuXi Biologics, Tigermed, and Sihuan Pharmaceutical, all rated as "Buy" [4]. - The report highlights the performance of specific companies, such as Sanofi and Jizhong Pharmaceutical, which have shown significant weekly gains [28]. Valuation Metrics - The pharmaceutical sector is currently valued at 21.9 times PE based on 2026 earnings forecasts, with a premium of 11% over the overall A-share market [21][22]. - The TTM valuation for the sector stands at 29.9 times PE, below the historical average of 34.8 times PE, indicating potential undervaluation [21][22].

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The pharmaceutical sector is experiencing a divergence in performance, with price increase logic and structural opportunities during the earnings window being noteworthy [7][11] - The report highlights the strong performance of the medical device sector, particularly in brain-computer interface policies and price increases for gloves, which are catalyzing market activity [11] - The "14th Five-Year Plan" has been released, clarifying the direction for the medical industry and system construction, emphasizing innovation in biomedicine and the integration of AI technologies [11][12] Summary by Sections Industry Overview - The pharmaceutical industry comprises 504 listed companies with a total market value of 69,254.89 billion [2] - The circulating market value stands at 63,426.67 billion [2] Market Dynamics - The Shanghai Composite Index rose by 0.19%, while the pharmaceutical sector fell by 0.22%, ranking 13th among 31 sub-industries [11] - The report notes a mixed performance across various segments, with medical devices and biological products showing positive trends [11] Key Recommendations - The report recommends focusing on sectors likely to see price increases, such as gloves and raw materials, as well as innovative drugs and AI applications [11] - Specific companies to watch include Innovent Biologics, Mindray Medical, and others in the innovative drug and medical device sectors [8][12] Policy and Regulatory Developments - The report discusses the approval of the first invasive brain-computer interface medical device, marking a significant milestone in the industry [16] - The "14th Five-Year Plan" outlines key technological advancements and legislative support for emerging industries, including biomedicine and AI [11][13]

Core Viewpoint - Market fluctuations are driven by various "expectations," with major expectations leading to trend-driven markets and minor expectations influencing trading markets [1]. Group 1: Market Conditions - The central bank conducted a 230 billion yuan reverse repurchase operation, with 320.5 billion yuan of reverse repos maturing today, resulting in a net withdrawal of 297.5 billion yuan [3]. - The interbank funding market showed a balanced and slightly loose liquidity, with DR001 around 1.27% and DR007 around 1.42% [3]. - The government work report met expectations, leading to a slight increase in the stock market, while the central bank's reduced 200 billion yuan buyout operation indicated a stable interest rate environment [5]. Group 2: Interest Rates and Bond Market - The 10-year government bond yield opened lower at 1.787% and fluctuated, with a slight increase to 1.79% before closing at 1.785% [5]. - The weighted average rates for various interbank funding instruments were as follows: R001 at 1.35% (up 2 basis points), R007 at 1.50%, and R014 at 1.52% [4]. Group 3: External Factors - Reports indicated that Iran is willing to negotiate, leading to a rebound in overseas risk assets [5]. - The geopolitical situation involving Iran has created a complex narrative, with military and diplomatic tensions affecting market sentiment [5].

Core Viewpoint - Shenzhen Jingming Pharmaceutical Co., Ltd. has been established with a registered capital of 40 million RMB, indicating a new player in the pharmaceutical manufacturing industry [1] Company Overview - Company Name: Shenzhen Jingming Pharmaceutical Co., Ltd. [1] - Legal Representative: Ye Wenfei [1] - Registered Capital: 40 million RMB [1] - Shareholder: Shanghai Jiaoming Business Service Co., Ltd. holds 100% [1] - Company Type: Limited Liability Company (wholly owned by a legal person) [1] - Business Duration: Until February 27, 2026, with no fixed term thereafter [1] Business Scope - General Business Activities: Technology services, development, consulting, exchange, transfer, and promotion related to technology; research and development of biochemical products [1] - Licensed Business Activities: Drug production, wholesale, entrusted production, and retail [1] - Note: Licensed activities require approval from relevant authorities before commencement [1] Industry Classification - National Standard Industry: Manufacturing > Pharmaceutical Manufacturing > Chemical Drug Preparation Manufacturing [1] - Location: 432F, 4th Floor, East A Factory, Wanli Industrial Park, Fubao Community, Fubao Street, Futian District, Shenzhen [1]

Group 1: Share Buybacks - Companies such as Zhongshun Jierou and Yuanli Co. have announced new share buyback plans, with Zhongshun Jierou planning to repurchase shares at a price not exceeding 12.4 yuan per share, with a total fund of no less than 60 million yuan and no more than 120 million yuan [1] - Kaipu Cloud plans to repurchase shares with a total fund of no less than 50 million yuan and no more than 100 million yuan, at a price not exceeding 315 yuan per share [1] - Aidi Precision has repurchased 209,000 shares for a total payment of approximately 5.09 million yuan, as part of a buyback plan with a total fund range of 100 million to 200 million yuan [3] Group 2: Shareholder Increases - Conch Cement's controlling shareholder, Conch Group, plans to increase its stake in the company with a minimum investment of 700 million yuan and a maximum of 1.4 billion yuan within six months [2] - Huaneng Hydropower's controlling shareholder's investment fund has increased its stake by 3.276 million shares for a total of 30.02 million yuan, with plans to continue increasing its stake by an estimated total of 100 million to 150 million yuan [2] - Fuguang Co. reported that its controlling shareholder has cumulatively increased its stake by 233,300 shares, costing approximately 6.76 million yuan, with plans for further increases [2] Group 3: Buyback Progress - Xingsui Technology has cumulatively repurchased 2.98 million shares, with total payments exceeding 68.41 million yuan, surpassing the lower limit of its buyback plan [3] - Jiutian Pharmaceutical has completed its buyback plan, having repurchased 6.1808 million shares, accounting for 1.24% of the total share capital, with a total transaction amount reaching 100 million yuan [3]